Marshall Wace North America L.P. purchased a new stake in Spectranetics Corp (NASDAQ:SPNC) during the second quarter, according to its most recent filing with the SEC. The fund purchased 173,005 shares of the medical equipment provider’s stock, valued at approximately $6,574,000. Marshall Wace North America L.P. owned about 0.39% of Spectranetics Corp as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. OppenheimerFunds Inc. boosted its stake in shares of Spectranetics Corp by 82.6% in the first quarter. OppenheimerFunds Inc. now owns 1,141,402 shares of the medical equipment provider’s stock valued at $33,243,000 after buying an additional 516,260 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Spectranetics Corp during the first quarter valued at $213,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Spectranetics Corp during the first quarter valued at $108,000. Point72 Asset Management L.P. boosted its stake in shares of Spectranetics Corp by 726.0% in the first quarter. Point72 Asset Management L.P. now owns 205,667 shares of the medical equipment provider’s stock valued at $5,990,000 after buying an additional 180,767 shares during the last quarter. Finally, Longfellow Investment Management Co. LLC acquired a new stake in shares of Spectranetics Corp during the second quarter valued at $1,771,000. 91.95% of the stock is owned by hedge funds and other institutional investors.

Spectranetics Corp (SPNC) opened at 38.45 on Tuesday. Spectranetics Corp has a 1-year low of $19.80 and a 1-year high of $38.55. The company’s 50 day moving average is $37.28 and its 200 day moving average is $30.10.

Spectranetics Corp (NASDAQ:SPNC) last released its earnings results on Thursday, August 3rd. The medical equipment provider reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.29. The business had revenue of $74.71 million for the quarter, compared to analysts’ expectations of $73.82 million. Spectranetics Corp had a negative net margin of 32.93% and a negative return on equity of 194.18%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.35) earnings per share. On average, analysts expect that Spectranetics Corp will post ($1.16) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “173,005 Shares in Spectranetics Corp (SPNC) Acquired by Marshall Wace North America L.P.” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/173005-shares-in-spectranetics-corp-spnc-acquired-by-marshall-wace-north-america-l-p/1529170.html.

Several equities research analysts have recently weighed in on SPNC shares. Canaccord Genuity cut shares of Spectranetics Corp from a “buy” rating to a “hold” rating and upped their price target for the stock from $37.00 to $38.50 in a research report on Monday, July 10th. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $27.00 price target on shares of Spectranetics Corp in a research report on Monday, July 24th. Zacks Investment Research cut shares of Spectranetics Corp from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd. ValuEngine raised shares of Spectranetics Corp from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $38.50 price target on shares of Spectranetics Corp in a research report on Wednesday, June 28th. Eleven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Spectranetics Corp presently has an average rating of “Hold” and an average price target of $35.36.

About Spectranetics Corp

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.

Institutional Ownership by Quarter for Spectranetics Corp (NASDAQ:SPNC)

Receive News & Ratings for Spectranetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectranetics Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.